Trial Profile
Multi-center, double-blind, placebo-controlled, randomized, parallel group study to evaluate the effects of different doses of SH T 00127B [asoprisnil] in women with treatment-resistant menorrhagia aged 30 to 55 years after daily oral administration of multiple doses for 35 up to 50 days
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2008
Price :
$35
*
At a glance
- Drugs Asoprisnil (Primary)
- Indications Menorrhagia
- Focus Therapeutic Use
- Sponsors Bayer
- 21 Jul 2006 New trial record.